摘要
目的:探讨醒脑静联合纳络酮对重症监护室(ICU)脑出血患者神经功能及GCS评分的影响。方法:选择2018年3月至2019年5月我院收治的ICU脑出血患者97例为研究对象,根据随机数字表法将其分为对照组(n=48)与观察组(n=49)。对照组用纳洛酮静脉滴注治疗,在此基础上观察组加用醒脑静静脉滴注治疗,比较两组临床疗效、神经功能、GCS评分及不良反应总发生率。结果:治疗两疗程后,观察组总有效率较对照组高,差异有统计学意义(P<0.05);治疗两疗程后,两组NIHSS评分均较治疗前下降,且观察组评分低于对照组,差异有统计学意义(P<0.05);治疗后,两组GCS评分均较治疗前提高,且观察组较对照组提高,差异有统计学意义(P<0.05);观察组不良反应发生率较对照组相比,差异无统计学意义(P>0.05)。结论:醒脑静联合纳络酮有利于ICU脑出血患者神经功能恢复,改善患者昏迷状态,且不良反应少,安全性高。
Objective:To investigate the effect of Xingnaojing combined with naloxone on the neurological function and GCS score of patients with cerebral hemorrhage in intensive care unit(ICU).Methods:97 patients with ICU intracerebral hemorrhage admitted in our hospital from March 2018 to May 2019 were selected as the study subjects,which were divided into control group(n=48)and observation group(n=49)according to the random digital table method.Control group was treated with naloxone intravenous drip,and the observation group was treated with Xingnao intravenous drip to compare the clinical efficacy,nerve function,GCS score and the total incidence of adverse reactions between the two groups.Results:After treatment of 2 courses of treatment,the observation group total The effective rate was higher than that of the control group(P<0.05);after the treatment of 2 courses,the NIHSS scores of the two groups were lower than before treatment,and the observation group score was lower than that of the control group,the difference was statistically significant(P<0.05);after treatment,the GCS scores of group,and the difference was statistically significant(P<0.05);the incidence of adverse reactions in the observation group was not statistically significant compared with the control group(PP<P<0.05).Conclusion:Xingnaojing combined with naloxone is beneficial to the recovery of nerve function and the improvement of coma state in patients with ICU cerebral hemorrhage less good reaction and high safety.
作者
刘琳琳
LIU Lin-lin(Department of Critical Medicine,the Seventh People's Hospital of Zhengzhou,Zhengzhou Henan 450000,China)
出处
《药品评价》
CAS
2020年第8期56-58,共3页
Drug Evaluation